COMMUNIQUÉS West-GlobeNewswire

Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
31/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
31/10/2025
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome [...]
PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt
31/10/2025
GOLDEN, Colo. and CAIRO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- PharmaJet ® , a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced [...]
Test And Tren Cycle For Muscle Growth - CrazyBulk Lunch Test and Tren Stack (Tren Max) Pills for Bodybuilding, Beginners Dosage, Benefits, Before And After Results
31/10/2025
CrazyBulk Introduce Test and Tren Stack for Bodybuilding, legal Steroids Alternative Pills for Test and Tren Cycle Read Dosage For Beginners, and (Tren Max) Pills Before And After Results NEW YORK, Oct. 31, 2025 (GLOBE [...]
Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
31/10/2025
CHICAGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the initiation of a new [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
31/10/2025
COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% [...]
Immuron Announces Clinical Trial Update
31/10/2025
IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan ® P2TD (n=851) Uniformed Services University study topline data delayed to the end [...]
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
31/10/2025
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 [...]
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
31/10/2025
Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care [...]
Upstream Bio to Participate in Upcoming November Investor Conferences
31/10/2025
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
31/10/2025
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with [...]
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
31/10/2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. 2025 [...]
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
31/10/2025
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in [...]
Vireo Growth Inc. to Release Third Quarter 2025 Results on November 12, 2025
31/10/2025
MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended [...]
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
31/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM [...]
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
31/10/2025
Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November [...]
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
31/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct [...]
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
31/10/2025
Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31/10/2025
COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its [...]

Pages